Skip to main content
. 2017 Dec 14;10(2):304–314. doi: 10.1080/19420862.2017.1409320

Figure 4.

Figure 4.

Pharmacokinetic determination of peripheral and brain drug levels following i.v. administration of isotype control and BBBt0626. C57BL/6 mice were injected via the tail vein with BBB targeting hIgG1 antibody or isotype control antibody. Sampling was performed at regular intervals for either 1 or three weeks to determine plasma exposure for each antibody. (A) Comparison of 21 day plasma exposure (μg/ml) of isotype control (NIP228) at 0.45 mg/kg (▾) 4.5 mg/kg (▪) and 45 mg/kg (•) or Bbbt0626 at 0.45 mg/kg (▾) 4.5 mg/kg (▪) and 45 mg/kg (•). (B) Comparison of 7 day plasma exposure (μg/ml) of isotype control (▴) or Bbbt0626 (•) hIgG1TM. (C) Brain exposure of isotype control (▴) and BBBt0626 (•) as measured by % injected dose per g brain for 1 week.